Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Aasander Frostner 2022 BEC

From Bioblast

Bioblast2022 banner.jpg


Bioenergetics Communications        
Gnaiger 2020 BEC MitoPathways
       
Gnaiger Erich et al ― MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1.
        MitoPedia: BEC         MitoPedia: Gentle Science         MitoFit Preprints         DOI Data Center
Bioenergetics Communications
Publications in the MiPMap
Åsander Frostner E, Simón Serrano S, Chamkha I, Donnelly E, Elmér E, Hansson MJ (2022) Towards a treatment for mitochondrial disease: current compounds in clinical development. https://doi.org/10.26124/bec:2022-0004

» Bioenerg Commun 2022.4. Open Access pdf published online 2022-06-28 »Watch the presentation«

Aasander Frostner Eleonor, Simon Serrano Sonia, Chamkha Imen, Donnelly Ellen, Elmer Eskil, Hansson Magnus J (BEC 2022.04) Bioenerg Commun

Abstract: BEC.png https://doi.org/10.26124/bec:2022-0004

Primary mitochondrial diseases are a heterogeneous group of rare genetic disorders affecting approximately 125 persons per million. Mutations underlying these diseases give rise to biological changes (including decrease in cellular energy production and increase in reactive oxygen species), leading to organ failure, and commonly early morbidity. Mitochondrial diseases often present in early childhood and lead to the development of severe symptoms, with severe fatigue and myopathy being some of the most prevalent and debilitating clinical signs.

There are currently no cures for mitochondrial diseases, nor any approved pharmaceutical treatments for multisystemic disorders.

Current drug development in mitochondrial diseases focuses mainly on modulation of oxidative stress, regulation of the expression of genes involved in metabolic pathways, modulation of coenzymes, induction of mitochondrial biogenesis, and energy replacement.

In this short review, we present the current landscape of mitochondrial disease drug development, focusing on small molecules in clinical trials conducted by industrial sponsors.

Keywords: pmitochondria, primary mitochondrial disease, genetic disorders, MELAS, myopathy
Bioblast editor: Tindle-Solomon Lisa O2k-Network Lab: SE Lund Elmer E

ORCID: ORCID.png Aasander Frostner Eleonor, ORCID.png Simon Serrano Sonia, ORCID.png Chamkha Imen, ORCID.png Donnelly Ellen, ORCID.png Elmer Eskil, ORCID.png Hansson Magnus J

Preprint

» Aasander Frostner 2022 MitoFit


Labels: MiParea: mt-Medicine, Pharmacology;toxicology  Pathology: Inherited  Stress:Mitochondrial disease  Organism: Human 





BEC